Menu Search
Equities

WuXi Biologics (Cayman) Inc

2269:HKG

WuXi Biologics (Cayman) Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)16.64
  • Today's Change-0.18 / -1.07%
  • Shares traded84.30m
  • 1 Year change-65.94%
  • Beta1.5732
Data delayed at least 15 minutes, as of Nov 12 2024 08:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year WuXi Biologics (Cayman) Inc had net income fall -23.09% from 4.42bn to 3.40bn despite a 11.56% increase in revenues from 15.27bn to 17.03bn. An increase in the cost of goods sold as a percentage of sales from 55.96% to 59.92% was a component in the falling net income despite rising revenues.
Gross margin38.66%
Net profit margin17.60%
Operating margin22.21%
Return on assets5.57%
Return on equity6.72%
Return on investment6.85%
More ▼

Cash flow in CNYView more

In 2023, WuXi Biologics (Cayman) Inc increased its cash reserves by 51.20%, or 3.27bn. The company earned 4.67bn from its operations for a Cash Flow Margin of 27.40%. In addition the company generated 1.96bn cash from financing while 3.23bn was spent on investing.
Cash flow per share1.14
Price/Cash flow per share14.30
Book value per share10.60
Tangible book value per share10.08
More ▼

Balance sheet in CNYView more

WuXi Biologics (Cayman) Inc has a Debt to Total Capital ratio of 9.28%, a lower figure than the previous year's 10.23%.
Current ratio2.91
Quick ratio2.62
Total debt/total equity0.1123
Total debt/total capital0.0928
More ▼

Growth rates in CNY

Year on year, growth in earnings per share excluding extraordinary items dropped -22.61%. Additionally, five year annualized earnings per share growth ranks highest in its industry.
EPS growth(5 years)37.34
EPS (TTM) vs
TTM 1 year ago		-36.10
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.